News for Vaxart, Inc. (NB11.DE)

SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Office

**media[578270]**

Operator: Greetings and welcome to the Vaxart Business Update and Fourth Quarter and Full Year 2024 Financial Results Conference call.

Cash Position: Cash, cash equivalents, and investments totaled $51.7 million as of December 31, 2024, providing financial runway through multiple development m

Mar 20, 2025 / 08:30PM GMTOperator Greetings and welcome to the Vaxart Business update in fourth quarter and full year 2024 financial results conference call. A

Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ETCompany ParticipantsEd Berg - SVP and General CounselSteven Lo -...

VAXART (VXRT) delivered earnings and revenue surprises of 50% and 51.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[572460]**

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced it will provide

- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced the initi

**media[558437]**

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

**media[526226]**

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

In a regulatory filing, Vaxart (VXRT) stated: “As previously disclosed on June 13, 2024, Vaxart, Inc. entered into an agreement with Advanced Technology International, the Consortium Management Firm of the Rapid Response Partnership Vehicle funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Pursuant to the Project Agreement, the Company receives funding for a Phase 2b comparative study evaluating the Company’s oral pill XBB C

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced completion of enrollment of the sentinel cohort of a Phase

**media[481355]**

Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsEdward Berg - Senior Vice President and General...

VAXART (VXRT) delivered earnings and revenue surprises of 40% and 70.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?